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Dear Editor,
With great interest, we read Seger’s review on chronic 
granulomatous disease (CGD).1 It is a very up-to-date and 
clear review. Seger refers to our observation that there 
is a strongly upregulated production of interleukin-1β 
in patients with CGD, demonstrating that a deficiency 
of NADPH-dependent reactive oxygen species leads to 
increased inflammasome activation.2 We have taken this 
observation further in a 39-year-old patient with CGD 
(p91-phox mutation), who was suffering from perirectal 
granulomas that were refractory against corticosteroid 
therapy. We treated the patient with recombinant 
interleukin-1 receptor antagonist (subcutaneous anakinra, 
100 mg daily) for three months with a good response.
In his review, Seger states that anti-TNF drugs may be 
used in such cases, but only for a short period, because of 
the infectious hazards. As anakinra is much safer in this 
respect,3,4 we would propose to try anakinra first in CGD 
patients with granulomas. Since anakinra has fewer side 
effects (pain and inflammation at the injection site due to 
the preservative) than corticosteroids one might even ask 
the question whether anakinra should be preferred over 
the latter drugs.
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